SLNO
Soleno Therapeutics Inc

8,044
Mkt Cap
$3.48B
Volume
1.23M
52W High
$90.32
52W Low
$41.50
PE Ratio
-15.79
SLNO Fundamentals
Price
$67.13
Prev Close
$65.45
Open
$65.44
50D MA
$65.13
Beta
0.74
Avg. Volume
2.43M
EPS (Annual)
-$4.38
P/B
13.75
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire...
PR Newswire·8d ago
News Placeholder
More News
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·8d ago
News Placeholder
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
Zacks·26d ago
News Placeholder
Soleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Soleno Therapeutics (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks·1mo ago
News Placeholder
Soleno Therapeutics Stock Tanks After Patient Treated With Drug Dies – More Details Inside
Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR.
Stocktwits·1mo ago
News Placeholder
Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·2mo ago
News Placeholder
Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet
The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure.
Stocktwits·2mo ago
News Placeholder
How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15%
The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Soleno Therapeutics (SLNO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·2mo ago
News Placeholder
Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going
Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zacks·2mo ago
News Placeholder
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates
Soleno Therapeutics (SLNO) delivered earnings and revenue surprises of +83.02% and +1.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago

Latest SLNO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.